Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Starling Oncology, Inc.

NASDAQ: STLN · Industrial Applications and Services · 6 alerts · CIK 1799191

Share price
$3.54Close, Nov 16
Market cap
$361M
Shares outstanding
101.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Offices & Clinics of Doctors of MedicineSIC 8011

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Starling Oncology, Inc. filings on SEC EDGAR ↗

6:03 AM ET 10-Q
Financial Results

Starling Oncology Q3 2026 Results: Net Loss of $15.7M, Loss Narrows

Starling Oncology, Inc. reported a significant revenue increase to $478.5 million for the nine months ended September 30, 2026, driven primarily by growth in its Specialty Pharmacy segment. Despite this growth, the company remains unprofitable with a net loss of $28.0 million for the period and a total stockholders' deficit of $37.4 million.

Key figure
Net loss $15.7M
4:58 PM ET 8-K
Financial Results

Starling Oncology Financial Results

Starling Oncology reported Q3 2026 consolidated revenue of $169.8 million, a 24.3% increase year-over-year, and achieved its second consecutive quarter of positive Adjusted EBITDA at $3.4 million. The company updated its full-year 2026 revenue guidance to $650-$660 million and raised the low end of its Adjusted EBITDA outlook to $4-$6 million.

Term
Q3 2026

“The third quarter of 2026 was another strong quarter for our company, with revenue up 24% year over year and Adjusted EBITDA of $3.4 million, our second consecutive quarter of positive Adjusted EBITDA and above our third quarter outlook of $0.50 million to $1.5 million. Our capitated business continues to deliver growth, with capitated revenue up 40% and MLR performing at expectations. Our Specialty pharmacy business grew 44% year over year, with strong gross margins of 24% for this segment. Starling Nexus, our proprietary provider-focused portal, is now live and available to our network clinicians to support care coordination and evidence-based care on our delegated capitation model. Based on our performance year to date, we are affirming our full-year 2026 guidance, and we believe we are well positioned for continued growth into 2027.”

Daniel Virnich, CEO of Starling

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.